A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Recruiting
Trial end date:
2026-09-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in
participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic
Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a
B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed were
intolerant to or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status
(Cohort 2).